# Meloxicam vs Placebo for Mobilization

> **NCT02003625** · PHASE2 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 31 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma
- Hodgkin's Lymphoma
- Multiple Myeloma
- Hematopoietic Stem Cells

## Interventions

- **DRUG:** GCSF
- **DRUG:** meloxicam
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02003625
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2019-02
- **Final completion:** 2019-04
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2020-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02003625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02003625, "Meloxicam vs Placebo for Mobilization". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02003625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*